Portfolio Lab

Bio-Rad Laboratories, Inc.

  • Stock
  • Ticker BIO
  • ISIN US0905722072
  • NYSE

Technology · Electronics and instruments · USA

$358.90 −2.34%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Bio-Rad Laboratories, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

BIOGlobal equities (VT)

$10,000 grew to $20,766. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −73.8% in 06/2025, measured from the peak in 09/2021. The old peak has not been reached again yet.

1-year return
+18.2%
5-year return p.a.
−14.3%
10-year return p.a.
+7.6%
Volatility p.a.
33.5%
Largest decline
−73.8%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue668585652653693592651656
Gross profit342306345343345309346329
Operating income58247765-1193473-50
Net income-71664318-342720-527371459
Earnings per share-25.572.2911.67-12.7026.39-19.5513.8517.02
Balance sheet
Total assets9,3649,52710,2149,69610,5779,79010,25210,783
Liabilities2,7952,8483,0852,9603,1232,9393,0783,180
Equity6,5696,6797,1296,7377,4546,8517,1747,603
Cash488521369396530507517465
Long-term debt1,2001,2011,2011,2011,202803803803
Cash flow
Operating cash flow1241301171211651089996
Capital expenditure-43-34-46-32-46-30-32-31
Free cash flow81967189119786765

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +59.3%, weakest 2022 at −44.3%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026$17.02
4 Aug 2026$13.85
30 Apr 2026−$19.55
13 Feb 2026$26.39
29 Oct 2025−$12.70
31 Jul 2025$11.67
1 May 2025$2.29
14 Feb 2025−$25.57
31 Oct 2024$23.34
2 Aug 2024−$76.26
8 May 2024$13.45
16 Feb 2024$12.14

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€8.8bn
Market cap in trading currency
$9.67bn
Enterprise value
$9.21bn
P/E
9.5
P/S
3.73
P/B
1.27
EV/Sales
3.55
EV/EBITDA
–
Earnings yield
10.5%
FCF yield
3.4%

Results (last four quarters)

Revenue
$2.59bn
Gross profit
$1.33bn
EBITDA
–
Net income
$1.02bn
Earnings per share
$37.71
Revenue per share
$96.22
Revenue growth
+0.5%
Earnings growth
–

Profitability

Gross margin
51.3%
Operating margin
-2.4%
Net margin
39.5%
Return on equity
14.3%
Return on assets
9.5%

Balance sheet and cash flow

Cash
$1.66bn
Cash per share
$61.77
Financial debt
$1.20bn
Debt/equity %
16
Current ratio
3.18
Book value per share
$282.17
Operating cash flow
$468m
Free cash flow
$329m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
26.9m
Volume
182,295
Avg. volume 3 months
257,158
Relative volume
0.7

Price and technicals

Price
$358.90
1 day
−2.3%
52-week high
$390.34
52-week low
$241.71
Distance to 52-week high
−8.1%
Distance to 52-week low
+48.5%
Distance to 50-day line
−3.4%
Distance to 200-day line
+12.7%
RSI (14)
43
Volatility 1M
34.0%

Performance

1 week
−2.0%
1 month
−1.3%
3 months
−6.0%
6 months
+24.7%
YTD
+18.5%
1 year
+17.8%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has BIO performed since 11/2016?

$10,000 grew to $20,766 by 20 Nov 2026, which is +7.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is BIO?

Volatility was 33.5% per year, measured on monthly returns. The largest decline from a peak was −73.8%, with the low in 06/2025.

How does BIO compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, BIO returned +7.6% at 33.5%. The correlation of monthly returns was 0.43; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Bio-Rad Laboratories, Inc. (BIO): Return and risk